vicebio - Search News

News

Vicebio, next-generation vaccine biotech

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

Reuters on MSN · 1d

France's Sanofi to acquire biotech firm Vicebio for $1.15 billion

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of $1.15 billion, expanding its respiratory vaccine portfolio.

MarketWatch · 1d

Vicebio, next-generation vaccine biotech, to be acquired by Sanofi for US$1.6 billion

Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond -- Lead asset VXB-241 is a bivalent vaccine targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV),

6hon MSN

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. A visit to the chiropractor can provide many health benefits.

Health Care Up Amid Deal Activity -- Health Care Roundup

Health care companies recouped some of their recent losses amid generally strong earnings and deal activity. British drug maker AstraZeneca said it plans to invest $50 billion in the U.S. by 2030, ...

Sanofi to Buy Vicebio for Up to $1.6 Billion in Vaccine Push

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results